

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal

Adalimumab for treating moderate to severe hidradenitis suppurativa [ID812]

Matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Company</u></p> <ul style="list-style-type: none"> AbbVie (adalimumab) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> Hidradenitis Suppurativa Trust <p><u>Professional groups</u></p> <ul style="list-style-type: none"> British Association of Dermatologists Royal College of Nursing Royal College of Physicians <p><u>Others</u></p> <ul style="list-style-type: none"> Department of Health NHS England Welsh Government 	<p><u>General</u></p> <ul style="list-style-type: none"> Department of Health, Social Services and Public Safety for Northern Ireland <p><u>Comparator companies</u></p> <ul style="list-style-type: none"> Allergan UK (retinoids, dapsons) (confidentiality agreement not signed, not participating). AstraZeneca (metformin) (confidentiality agreement not signed, not participating). Auden Mckenzie (dapsons) (confidentiality agreement not signed, not participating). Boehringer Ingelheim (metformin) Crawford Healthcare (clindamycin) (confidentiality agreement not signed, not participating). Genus Pharmaceuticals (retinoids, metformin) (confidentiality agreement not signed, not participating). GlaxoSmithKline (isotretinoin) (confidentiality agreement not signed, not participating). Hospira UK (infliximab biosimilar, Inflectra) (confidentiality agreement not signed, not participating). Janssen-Cilag (metformin) Merck Sharp & Dohme Ltd (infliximab, metformin) Napp Pharmaceuticals (infliximab biosimilar, Remsima) (confidentiality agreement not signed, not

National Institute for Health and Care Excellence

Matrix for the technology appraisal of adalimumab for treating moderate to severe hidradenitis suppurativa [ID812]

Updated: October 2015

Page 1 of 3

Consultees	Commentators (no right to submit or appeal)
	<p><i>participating</i>).</p> <ul style="list-style-type: none"> • Novartis (metformin) (<i>confidentiality agreement not signed, not participating</i>). • Pfizer (clindamycin) (<i>confidentiality agreement not signed, not participating</i>). • Rosemont Pharmaceutical (metformin) • Sanofi (rifampicine) (<i>confidentiality agreement not signed, not participating</i>). • Takeda (metformin) (<i>confidentiality agreement not signed, not participating</i>). • TEVA (erythromycin) (<i>confidentiality agreement not signed, not participating</i>). • Wockhardt (metformin) (<i>confidentiality agreement not signed, not participating</i>). • Zentiva (metformin) (<i>confidentiality agreement not signed, not participating</i>). <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> • Public Health England • Public Health Wales

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

Definitions:

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Determination (FAD).

All non-company consultees are invited to submit a statement¹, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: companies that market comparator technologies;

Healthcare Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and NHS Commercial Medicines Unit, and the *British National Formulary*).

All non-company commentators are invited to nominate clinical specialists or patient experts.

¹Non-company consultees are invited to submit statements relevant to the group they are representing.